Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris
| Status: | Completed |
|---|---|
| Conditions: | Acne, Acne, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/5/2014 |
| Start Date: | April 2014 |
| End Date: | October 2014 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
A Phase 2a Randomized, Double-blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability And Effects Of PF-05175157 On Moderate To Severe Acne Vulgaris In Adult Subjects
This is a 6 week study to characterize the safety, tolerability and effects of PF-05175157
administered for 6 weeks in subjects with moderate to severe acne vulgaris.
administered for 6 weeks in subjects with moderate to severe acne vulgaris.
Inclusion Criteria:
- Males 18 years or older diagnosed with moderate to severe acne vulgaris who are
otherwise healthy.
- Normal spirometry at screening (FEV1 and FVC (Forced Vital Capacity)at least 80%
predicted).
- Minimum of 20 inflammatory lesions on the face.
- Willing to discontinue other acne treatments prior to and during the study period
through follow-up.
Exclusion Criteria:
- Subjects with active nodulocystic acne.
- Subjects unwilling to comply with lifestyle guidelines, commit to study visits, and
perform study procedures.
- History of dry eye or other known disease that affects the sclera or cornea.
- History of pulmonary disease or inability to adequately perform testing.
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials